Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm...
Clinical Trial
Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
Matthew Hawryluk, Ph.D. POAI Board of DirectorsEAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is...
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE...
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with...
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101...
Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using...
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial...
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer...
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage...
BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer
REGULATED INFORMATION Appointment to further integrate BioSenic’s both cell therapy and autoimmune disease platforms under the responsibility of a new...
Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting...
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib...
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today...
Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)
First patient dosed in Phase 1b study of CTX-471 in combination with KEYTRUDA® in cancers of the lung, head and...
Carrick Therapeutics Closes Series C Financing
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN,...
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live moderated panel discussion on Thursday,...
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
Initial CD388 clinical data expected in the first half of 2023SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics,...